ASK YOUR DENTAL PROFESSIONAL...
Product Details Oraqix®, don't get stuck without it!
Oraqix® is needle-free and avoids lingering numbness in the lips and tongue.
 Clinical studies have shown Oraqix® to be safe and effective in providing patient pain-relief that is sufficient during scaling and/or root planing procedures in adults.
Oraqix® is a an anesthetic mixture applied to the gingival margin and periodontal pockets surrounding your teeth, using a needle-free, blunt tip applicator.
Oraqix® has rapid onset of action that begins within about 30 seconds of application and lasts for approximately 20 minutes (overall patient range 14-31 minutes).
Oraqix® can be applied to a single tooth or the whole mouth, providing anesthetic effect precisely where and when it is needed.
Oraqix® can be applied to several quadrants of teeth during a single visit.
And, Oraqix® can be used if needed, up to a maximum of 5 cartridges (8.5g of gel) per visit.
Oraqix® has not been studied in pediatric patients.
Contraindications
Oraqix® is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type or to any other component of this product.
Warnings
Prilocaine can cause elevated methemoglobin levels particularly in conjuction with methemoglobin-inducing agents. Methemoglobinemia has also been reported in a few cases in association with lidocaine treatment. Patients with glucose-6-phosphate dehydrogenase deficeincy or congenital or idiopathic methemoglobinemia are more susceptible to drug-induced methemoglobinemia. Oraqix® should not be used in those patients with congenital or idiopathic metheglobonemia and in infants under the age of twelve months who are receiving treatment with methemoglobin-inducing agents. Signs and symptoms of methemoglobinemia may be delayed some hours after exposure. Initial signs and symptoms of methemoglobinemia are characterized by a slate grey cyanosis seen in, e.g., buccal mucous membranes, lips and nail beds. In severe cases symptoms may include central cyanosis, headache, lethargy, dizziness, fatigue, syncope, dyspnea, CNS depression, dysrhythmia and shock. Methemoglobinemia should be considered if central cyanosis unresponsive to oxygen therapy occurs, especially if metHb-inducing agents have been used. Calculated oxygen saturation and pulse oximetry are inaccurate in the setting of methemoglobinemia. The diagnosis can be confirmed by an elevated methemoglobin level measured with co-oximetry. Normally metHb levels are <1%, and cyanosis may not be evident until a level of at least 10% is present. The development of methemoglobinemia is generally dose related. The individual maximum level of metHb in blood ranged from 0.8% to 1.7% following administration of the maximum dose of 8.5g Oraqix®. (Please see the Oraqix® Prescribing Information for more information)
Adverse Reactions
Following SRP treatment with Oraqix® in 391 patients (please see Oraqix® Prescribing Information for chart), the most frequent adverse events were local reactions in the oral cavity. These events, which occurred in approximately 15% of patients, included pain, soreness, irritation, numbness, vesicles, ulcerations, edema and/or redness in the treated area. Of the 391 patients treated with Oraqix, five developed ulcerative lesions and two developed vesicles of mild to moderate severity near the site of SRP. In addition, ulcerative lesions in or near the treated area were also reported for three out of 168 patients who received placebo. Other symptoms reported in more than one patient were headache, taste perversion, nausea, fatigue, flu, respiratory infection, musculoskeletal pain and accident/injury.
Oraqix® Prescribing Information (PDF doc)
Oraqix does not prevent gum disease or periodontitis. |
